Welcome to visit us at ATS2025
Non-Invasive Small Airway Liquid Biopsy at ATS & RIS 2025
We would be happy to meet with you in San Francisco!
PExA will exhibit at Booth #256 at ATS 2025 and is proud to be selected as a Featured Poster Company at the Respiratory Innovation Summit (RIS).
PExA is a non-invasive platform that enables biomarker discovery in the distal lung – the site where many respiratory diseases begin. By providing access to undiluted respiratory tract lining fluid (RTLF), PExA enables molecular insights directly from the small airways.
We believe that early and precise detection is essential to improving outcomes – not least in Lung Cancer, where diagnosis often comes too late. By enabling sampling where disease starts, PExA is paving the way for the next generation of respiratory diagnostics.
🎯 Unlocking the Deep Lung – Sample where it matters
PExA enables precise, repeatable sampling from the distal airways – where many respiratory diseases start and progress to an untreatable state.
Our unique, non-invasive technology collects undiluted RTLF for molecular analysis – paving the way for future early and precise diagnostics.
💊 Pharmacokinetics – Drug Insight at Site-of-Action
PEx sampling has shown proof-of-principle for measuring drug levels in the deep lung – ideal for PK studies on inhaled or targeted therapies.
🧪 Enhanced Biochemical Analysis
PEx samples are compatible with a number of different biochemical platforms and we can help you detected and analyze hundreds of potential biomarkers, including, proteins, lipids and miRNAs in this novel matrix.
📊 Introducing the Small Airway Atlas™
Preview the Small Airway Atlas, a first-of-its-kind initiative that compiles and maps key omics data from the small airways. We invite you to contribute to this growing resource, shaping the future of respiratory research.
📈 Use Cases & Publications
There are several studies ongoing using PExA within a broad range of respiratory conditions including Lung Cancer, COPD, asthma, ARDS, pulmonary embolism, occupational exposure and COVID-19.
So far PExA usage is supported by 50+ peer-reviewed publications.
📍 Welcome to meet Us at ATS 2025
– Booth #256: Live demo of PExA 2.1* and the Small Airway Atlas
– Featured Poster Company at RIS
– Book a Zoom if you’re not attending in person
Looking forward to see you in San Francisco!
Tomas, Jörgen, Svante
Recent publications using PExA include:
📄 Assessing Human Lung Pharmacokinetics Using Exhaled Breath Particles
📄 Particles in Exhaled Air (PExA): Clinical Uses and Future Implications
🔗 List of publications involving PExA’s method at PExA website